Project Grant R01HL173611
Award Date
1/15/25
Completion Date
11/30/28
Dollars Obligated
$601K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Virginia, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $764,817 to the University of North Carolina at Chapel Hill to conduct research on the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The study aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/Annexin A2/tissue plasminogen activator and the urokinase-type plasminogen...
This $157,784 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on the role of lactate metabolism in the progression of myelofibrosis, a type of myeloproliferative neoplasm that causes bone marrow scarring. The research aims to determine if inhibiting the lactate transporter MCT4 can prevent the differentiation of mesenchymal stromal cells into pro-fibrotic myofibroblasts, which drive disease...
This federal Project Grant award for $657,368.00, issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms controlling microRNA (miRNA) processing and degradation pathways during hematopoietic development. The primary awardee, The Washington University, will utilize human pluripotent stem cell lines with mutations in miRNA deadenylases and exosome components to identify novel...
This federal Project Grant award of $930,481.00 from the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research on synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesis. The research will be conducted by a K12 postdoctoral scholar at the University of North Texas, a Hispanic-serving research institution. The key objectives are to determine the nature of interaction between the...
This $2,352,138 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to model cell-specific signaling of the Low-Density Lipoprotein Receptor-Related Protein 1 (LRP1) in acute myocardial infarction (AMI). The research aims to expand and validate signaling networks that predict how early LRP1 signaling in cardiomyocytes enhances cell survival after ischemia-reperfusion, as well as how late...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $112,034 to the Rector & Visitors of the University of Virginia (UVA) to support research on the mechanisms controlling arterial-venous specification during embryonic vascular development. The key objectives are to: Rigorously define the cell cycle state of arterial and venous endothelial cells in the developing embryo using FUCCI2...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $780,120 to New York University (NYU) School of Medicine to define targetable vulnerabilities in UBA1-mutated hematopoietic stem cells (HSCs) for clonal eradication. The researchers will use advanced single-cell multi-omics techniques to map the impact of UBA1 mutations on HSC chromatin profiles, gene expression, and protein expression,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $3,007,209 to The University of Texas Health Science Center at Tyler (UTHSCT) to investigate the role of Gab2-MALT1-mediated cell signaling in venous thromboembolism (VTE) pathogenesis. The research aims to elucidate the molecular mechanisms by which the Gab2 signaling adapter protein and the MALT1 protein mediate...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $552,413 to Thomas Jefferson University (Sidney Kimmel Medical College) for research focused on understanding platelet and megakaryocyte function through the use of short inhibitory RNAs (siRNAs). The key goals are to: 1) investigate siRNA-mediated in vivo knockdown of the P2Y12 receptor to modulate thrombosis without compromising hemostasis; 2) investigate...
This $444,952 federal Project Grant award, titled "Exploring the Impact of Base Deaminase Deregulation on Precancer Evolution," was provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research) to the University of California, San Diego (UC San Diego). The goal of this 5-year research project is to investigate how deregulation of the APOBEC3C and ADAR1 base deaminase enzymes drives the transformation of pre-leukemic stem cells (pre-LSCs) into more aggressive...